---
title: "Integrity's net profit for 2024 is 8.5431 million yuan, a year-on-year decrease of 72.53%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/229718294.md"
description: "Integrity released its 2024 annual performance report, with operating revenue of 356 million yuan, a year-on-year decrease of 9.99%; net profit of 8.5431 million yuan, a year-on-year decrease of 72.53%; and a net loss of 1.8809 million yuan after deducting non-recurring gains and losses. The company's performance decline is mainly affected by the macroeconomic environment, reduced client budgets, and project delivery delays, while R&D investment continues to increase to maintain technological competitiveness"
datetime: "2025-02-26T08:44:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/229718294.md)
  - [en](https://longbridge.com/en/news/229718294.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/229718294.md)
generator: "portal-rs"
---

# Integrity's net profit for 2024 is 8.5431 million yuan, a year-on-year decrease of 72.53%

According to the Zhitong Finance APP, Integrity (688244.SH) disclosed its performance report for the year 2024, with operating revenue of 356 million yuan, a year-on-year decrease of 9.99%; net profit attributable to the parent company's owners was 8.5431 million yuan, a year-on-year decrease of 72.53%; and net loss attributable to the parent company's owners, after deducting non-recurring gains and losses, was 1.8809 million yuan. Basic earnings per share were 0.08 yuan.

During the reporting period, affected by macroeconomic factors, some clients reduced their budget investments, and there were delays in the signing, delivery, and acceptance of certain projects, resulting in the company's overall operating revenue falling short of expectations, down 9.99% year-on-year. At the same time, in order to maintain technological advancement and enhance core competitiveness, the company continued to increase its R&D investment. These factors contributed to the decline in the company's performance

### Related Stocks

- [688244.CN](https://longbridge.com/en/quote/688244.CN.md)

## Related News & Research

- [Movida releases 2Q26 institutional presentation factsheet](https://longbridge.com/en/news/296495308.md)
- [CANSINOBIO  Tetanus Vaccine New Drug Application Approved](https://longbridge.com/en/news/296498620.md)
- [CanSino Biologics says China NMPA approves adsorbed tetanus vaccine NDA](https://longbridge.com/en/news/296476562.md)
- [BUZZ-Life insurance stock weakness after Mark Walter headlines overdone, Evercore says](https://longbridge.com/en/news/296214606.md)
- [PEB: Draft Medicare coverage for Cxbladder tests marks a pivotal step toward renewed growth](https://longbridge.com/en/news/296426151.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**